Viridian Therapeutics, Inc.\DE: directors' dealings · United States · SEC (Form 4)

About Viridian Therapeutics, Inc.\DE

Viridian Therapeutics, Inc. is a US biotechnology company listed on the Nasdaq market (United States) under the ticker VRDN. Headquartered in Waltham, Massachusetts, Viridian is focused on developing potentially best-in-class medicines for autoimmune and rare diseases, with its most advanced and commercially relevant efforts centered on thyroid eye disease (TED). The company was originally founded in January 2010 as a Delaware LLC, later incorporated in June 2014, and adopted the Viridian Therapeutics name following the merger with miRagen Therapeutics in January 2021. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm?utm_source=openai)) Viridian’s business model is built around antibody discovery and protein engineering. Rather than pursuing entirely novel biology for its own sake, the company targets clinically validated pathways where existing therapies leave meaningful unmet need, aiming to improve efficacy, tolerability, and convenience. That framework is especially visible in TED, an autoimmune disease that can cause eye bulging, pain, double vision, and loss of quality of life. Viridian has framed its mission as improving treatment options for patients with autoimmune and rare diseases and has repeatedly emphasized differentiated clinical activity and easier administration as core design goals. ([viridiantherapeutics.com](https://www.viridiantherapeutics.com/about/?utm_source=openai)) The company’s lead assets are veligrotug, formerly VRDN-001, an intravenous anti-IGF-1R antibody, and elegrobart, formerly VRDN-003, a subcutaneous anti-IGF-1R candidate designed for more convenient delivery. Both programs have generated positive Phase 3 data in active and chronic TED. In 2025, Viridian received FDA Breakthrough Therapy Designation for veligrotug, submitted its BLA, and obtained Priority Review with a PDUFA target action date of June 30, 2026. In 2026, the company also reported positive topline data from the REVEAL-1 and REVEAL-2 Phase 3 studies for elegrobart, strengthening the commercial and clinical case for a broader TED franchise. ([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Receives-FDA-Breakthrough-Therapy-Designation-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease-TED/default.aspx?utm_source=openai)) From a competitive standpoint, Viridian is trying to differentiate itself through a combination of clinical potency, fewer infusions, and, for the subcutaneous version, potentially improved patient convenience and physician adoption. Management has said the goal is to establish veligrotug and elegrobart as foundational therapies in TED, with U.S. launch preparation underway and a European filing strategy also in motion. Beyond TED, the pipeline includes earlier-stage programs such as VRDN-006 and VRDN-008, as well as other autoimmune-focused assets, suggesting that TED is the first commercial platform rather than the company’s only long-term opportunity. ([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Highlights-Recent-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results?utm_source=openai)) For investors, Viridian is best viewed as a catalyst-driven biotech with meaningful execution risk but substantial upside if regulatory and launch milestones are met. Recent headlines have centered on the veligrotug regulatory path, positive elegrobart readouts, and a strengthened balance sheet, all of which support the company’s transition from pure R&D toward potential commercialization. ([investors.viridiantherapeutics.com](https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Elegrobart-Phase-3-REVEAL1-Clinical-Trial-in-Active-Thyroid-Eye-Disease/default.aspx?utm_source=openai))